M 7583

Drug Profile

M 7583

Latest Information Update: 11 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator EMD Serono
  • Class Antineoplastics
  • Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II B cell lymphoma

Most Recent Events

  • 04 Oct 2017 Merck plans a phase I trial in Healthy volunteers in Germany (NCT03297983)
  • 02 Jun 2017 Interim adverse events data from a phase I/II trial in B-cell lymphoma presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
  • 01 Aug 2016 Phase-I/II clinical trials in B-cell lymphoma (Second-line therapy or greater) in Germany (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top